During the second half of 2025, Rifampicin prices in India remained largely stable following the annual Wholesale Price Index (WPI)-linked revision of 1.74% implemented from April 2025. No additional broad-based WPI adjustment was introduced during H2, and prices continued to be governed under the National Pharmaceutical Pricing Authority's (NPPA) ceiling price framework. Manufacturers maintained compliance with notified ceiling prices while ensuring an uninterrupted supply of this essential anti-tuberculosis medicine. Routine retail price notifications issued by the NPPA during the period reflected continued regulatory oversight rather than significant market-driven price revisions.
Government price controls continued to shield the domestic market from fluctuations in raw material and manufacturing costs, keeping Rifampicin affordable despite inflationary pressures affecting the broader pharmaceutical industry. Manufacturers were required to adhere to prescribed ceiling prices, while retailers continued displaying updated prices in accordance with regulatory requirements. Overall, the market exhibited a stable pricing trend during H2 2025, with regulatory mechanisms remaining the primary factor influencing Rifampicin prices rather than supply-demand imbalances.